Your session has expired. Please click "Refresh" to refresh the page.
Nuclear Receptor Signaling Atlas
A research resource for the nuclear receptor signaling community
Newsletter Sign Up
AA420328 ; AU041214 ; ER ; ER-alpha ; ERALPHA ; ER[a] ; ERa ; ERalpha ; ESR ; ESR1 ; ESRA ; ESTRR ; Er alpha ; Era ; Esr ; Esr1 ; Estr ; Estra ; NR3A1 ; Nr3a1 ; RNESTROR ; eralpha ; esr1 ; estradiol receptor ; estrogen nuclear receptor alpha more...
AA420328; AU041214; ER; ER-alpha; ERALPHA; ER[a]; ERa; ERalpha; ESR; ESR1; ESRA; ESTRR; Er alpha; Era; Esr; Esr1; Estr; Estra; NR3A1; Nr3a1; RNESTROR; eralpha; esr1; estradiol receptor; estrogen nuclear receptor alpha; estrogen receptor; estrogen receptor 1 (alpha); estrogen receptor alpha; estrogen receptor alpha 3*,4,5,6,7*/822 isoform; estrogen receptor alpha E1-E2-1-2; estrogen receptor alpha E1-N2-E2-1-2; estrogen receptor alpha delta 3*,4,5,6,7*,8*/941 isoform; estrogen receptor alpha delta 3*,4,5,6,7*/819-2 isoform; estrogen receptor alpha delta 4 +49 isoform; estrogen receptor alpha delta 4*,5,6,7*/654 isoform; estrogen receptor alpha delta 4*,5,6,7,8*/901 isoform; estrogen receptor alpha variant delta 4; estrogen receptor protein; estrogen receptor, alpha; nuclear receptor subfamily 3 group A member 1; zfER[a]
Estrogen receptor α
Official Symbol
No records found.
ER-α is a 17β-estradiol-activated steroid receptor member of the nuclear receptor superfamily of transcription factors. It has a variety of central physiological roles, including those involved in maintenance of the reproductive, cardiovascular, musculoskeletal and central nervous systems. ER-α is expressed at low to moderate levels in major physiological systems (central nervous system (CNS), endocrine, metabolic, gastrointestinal, immune, reproductive, cardiovascular, respiratory and structural), with peaks of expression in the pituitary, ovary, uterus and vas deferens. ER-α dysfunction is associated with cancer (bone cancer, breast cancer, colorectal cancer, endometrial cancer, prostate cancer and uterine cancer), central nervous system (CNS) defects (alcoholism, migraine), cardiovascular system defects (aortic aneurysm, susceptibility to myocardial infarction, aortic valve sclerosis, cardiovascular disease, coronary artery disease, hypertension), hematological system defects (deep vein thrombosis), immune and inflammation diseases (Graves' Disease, arthritis, multiple sclerosis, cirrhosis), susceptibility to infection (hepatitis B, chronic liver disease), metabolic defects (bone density, cholestasis, hypospadias, obesity, osteoarthritis, osteopenia, osteoporosis), neurological defects (Alzheimer's disease, Parkinson's disease, migraine, vertigo), psychiatric defects (anorexia nervosa, attention deficit hyperactivity disorder (ADHD), dementia, major depressive disorder, psychosis) and reproductive defects (age of menarche, endometriosis, infertility). Targeted deletion (knockout) of ER-α results in defects in the central nervous system (CNS), the immune system, the musculoskeletal system, and the reproductive system.
Original References:
Greene GL, Gilna P, Waterfield M, Baker A, Hort Y and Shine J (1986) Sequence and expression of human estrogen receptor complementary DNA. Science 231 1150-4 View Abstract | View PubMed
Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P and Chambon P (0) Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 64 134-9 View Abstract | View PubMed
Pink JJ, Wu SQ, Wolf DM, Bilimoria MM and Jordan VC (1996) A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res. 24 962-9 View Abstract | View PubMed
GO Terms
Crystal Structures
Post-Translational Modifications
Protein-Protein Interactions
Targeting miRNAs
Clinical Trials
Animal Models